Nursing care
Sulfasalazine: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Sulfasalazine is contraindicated in patients with a sulfa allergy, since it is a sulfonamide combined with 5-aminosalicylic acid. Before giving it, confirm allergy status, encourage at least two litres of fluid daily to protect the kidneys from crystalluria, and expect the patient's urine and skin to turn orange-yellow, which is harmless.
Why this drug and not another
Sulfasalazine is used for ulcerative colitis, Crohn's disease, and rheumatoid arthritis because it combines a sulfonamide antibiotic component with 5-aminosalicylic acid, giving it both anti-inflammatory and antibacterial activity in the gut. It is often chosen over plain mesalamine when a patient also has joint involvement, as in rheumatoid arthritis, since it has disease-modifying activity there that mesalamine does not.
It is not the first choice for a patient with an established sulfa allergy, since the sulfapyridine component is structurally a sulfonamide and can trigger the same hypersensitivity reactions as sulfa antibiotics. This allergy history is the single most important prescribing check before the drug is started.
Administration and timing
Give sulfasalazine with food to reduce gastrointestinal upset, and give enteric-coated tablets whole, without crushing or chewing, since the coating protects the drug until it reaches the colon where much of its action occurs. Space doses evenly through the day as ordered, typically in divided doses, to maintain steady levels.
Encourage the patient to drink at least two litres of fluid a day while on this drug. Sulfasalazine and its metabolites can crystallise in concentrated urine, and adequate hydration reduces the risk of crystalluria and protects renal function, particularly in a patient who is also losing fluid through diarrhoea from active bowel disease.
Monitoring parameters
Baseline and periodic complete blood counts are needed because sulfasalazine can cause blood dyscrasias, including leukopenia, agranulocytosis, and megaloblastic anaemia related to folate deficiency. The drug interferes with folate absorption, so many patients are co-prescribed a folic acid supplement, and low folate should be anticipated rather than treated as an incidental finding.
Monitor liver function tests periodically, since hepatotoxicity is a recognised risk. In a patient with rheumatoid arthritis, also track symptom response such as joint swelling and pain, and in a patient with inflammatory bowel disease, track stool frequency and consistency as markers of disease control.
Adverse effects to report
Sore throat, fever, unusual bruising, or bleeding should be reported immediately, as these can be early signs of a blood dyscrasia and warrant an urgent complete blood count. Yellowing of the skin or eyes, dark urine unrelated to the drug's expected orange tint, or right upper quadrant pain suggests hepatotoxicity and should also be reported promptly.
A skin rash, especially one with blistering or mucous membrane involvement, needs urgent evaluation, since sulfonamide-related severe cutaneous reactions such as Stevens-Johnson syndrome, though rare, are serious. Persistent nausea, headache, or oligospermia in male patients are known but less urgent effects worth documenting.
Contraindications and cautions
A known sulfa allergy is a contraindication, and this must be confirmed before the first dose is given, since cross-reactivity with sulfa antibiotics is well established. Sulfasalazine is also contraindicated in patients with intestinal or urinary obstruction and used with caution in significant renal or hepatic impairment.
Use caution in patients with glucose-6-phosphate dehydrogenase deficiency, since sulfonamides can precipitate haemolysis in this population. In pregnancy, folate supplementation becomes especially important given the drug's effect on folate absorption and the role of folate in preventing neural tube defects.
Teaching points the exam tests
Teach the patient that orange-yellow discolouration of urine, sweat, and even soft contact lenses is an expected, harmless effect of the drug and does not indicate a problem. This is a commonly tested point because students sometimes mistake it for a sign of liver injury.
Teach the patient to maintain fluid intake around two litres a day to reduce the risk of crystals forming in the urine, and to take the medication with food at evenly spaced times. Reinforce that any sore throat, fever, unexplained bruising, or rash should be reported without delay, and that regular blood tests are part of ongoing safety monitoring, not an optional extra.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our gastrointestinal practice questions are the closest set to what this page covers.
Common questions
Can sulfasalazine be given to a patient allergic to sulfa drugs?
No. Sulfasalazine contains a sulfapyridine component that is chemically a sulfonamide, and a documented sulfa allergy is a contraindication. Confirm allergy history before the first dose and notify the prescriber if one is present.
Why does sulfasalazine turn urine orange?
The drug and its metabolites are naturally orange-yellow in colour, and this tint is excreted in urine, sweat, and other body fluids. It is a harmless, expected effect and does not indicate liver or kidney injury.
Why is folic acid often given with sulfasalazine?
Sulfasalazine impairs intestinal absorption of folate, which can lead to megaloblastic anaemia over time. A folic acid supplement is commonly prescribed alongside it to prevent this deficiency.
How much fluid should a patient on sulfasalazine drink?
At least two litres of fluid a day is generally recommended to reduce the risk of the drug or its metabolites crystallising in the urine. This is particularly important in a patient who is also losing fluid through diarrhoea.